[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Chan KW, Lee PY, Lam AK, Law S, Wong J, Srivastava G: Clinical relevance of Fas expression in oesophageal squamous cell carcinoma. J Clin Pathol; 2006 Jan;59(1):101-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical relevance of Fas expression in oesophageal squamous cell carcinoma.
  • AIMS: To determine the extent of Fas expression in oesophageal squamous cell carcinomas (ESCCs) from Chinese patients and to correlate Fas expression with clinicopathological prognostic parameters.
  • METHODS: Clinicopathological data were collected from 58 patients with ESCC who underwent oesophagectomy and had no prior radiotherapy or chemotherapy.
  • Expression of Fas was correlated with patients' demographics, tumour characteristics and stage, R category of surgery, and patients' survival.
  • This molecular pathway may be a potential therapeutic target for ESCC.
  • [MeSH-major] Antigens, CD95 / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Esophageal Neoplasms / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Feb 1;88(3):524-8 [10649242.001]
  • [Cites] J Gastrointest Surg. 2005 Feb;9(2):291-310 [15694827.001]
  • [Cites] Int J Oncol. 2002 Feb;20(2):291-7 [11788891.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5389-92 [12359741.001]
  • [Cites] Ann Surg. 2003 Sep;238(3):339-47; discussion 347-8 [14501500.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 7;96(13):1030-6 [15240787.001]
  • [Cites] Cancer. 1994 Jul 15;74(2):586-91 [8033037.001]
  • [Cites] Science. 1994 Jul 22;265(5171):528-30 [7518614.001]
  • [Cites] Science. 1995 Nov 17;270(5239):1189-92 [7502042.001]
  • [Cites] Virchows Arch. 1995;427(3):271-6 [7496596.001]
  • [Cites] Annu Rev Immunol. 1996;14:207-32 [8717513.001]
  • [Cites] J Immunol. 1998 Mar 1;160(5):2065-71 [9498742.001]
  • [Cites] J Immunol. 1998 Jun 1;160(11):5669-75 [9605174.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2057-62 [9605741.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3018-24 [9787134.001]
  • [Cites] Dis Esophagus. 1999;12(2):90-8 [10466040.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2464-9 [10499620.001]
  • [Cites] Pharmacol Ther. 2000 Dec;88(3):333-47 [11337030.001]
  • (PMID = 16394289.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1860271
  •  go-up   go-down


2. Gotoda T, Matsumura Y, Kondo H, Ono H, Kanamoto A, Kato H, Watanabe H, Tachimori Y, Nakanishi Y, Kakizoe T: Expression of CD44 variants and prognosis in oesophageal squamous cell carcinoma. Gut; 2000 Jan;46(1):14-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD44 variants and prognosis in oesophageal squamous cell carcinoma.
  • AIMS: To investigate whether CD44v, especially the CD44v2 (v2) isoform, may be a useful prognostic factor for patients with oesophageal squamous cell carcinoma, using a recently developed monoclonal antibody against a v2 epitope.
  • PATIENTS: 233 patients (211 men and 22 women; mean age 61.9 years), with oesophageal squamous cell carcinomas curatively removed without additional treatment between 1987 and 1996 at the National Cancer Center Hospital, were analysed for CD44v expression.
  • METHODS: The expression of CD44v was evaluated immunohistochemically using monoclonal antibodies against epitopes of the standard and variant protein, in paraffin embedded oesophageal squamous cell carcinoma tissue from 233 patients who had undergone cervical, mediastinal, and abdominal lymphadenectomy (three field dissection) for oesophagectomy.
  • RESULTS: Although total CD44 and CD44v6 (v6) were respectively observed in 99% and 97% of the cancer specimens, the expression of v2 was only 30%.
  • CONCLUSIONS: These results indicate that v2 is a useful marker for clinical prognosis in patients with oesophageal squamous cell carcinoma.
  • Particularly in patients without lymph node metastasis, v2 status may thus have implications for the use of adjuvant chemotherapy and/or radiotherapy in patients with oesophageal cancer at an early stage.
  • [MeSH-major] Antigens, CD44 / metabolism. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Esophageal Neoplasms / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1987 Aug;105(2):983-90 [2442176.001]
  • [Cites] J Surg Oncol. 1998 Mar;67(3):160-3 [9530885.001]
  • [Cites] Cell. 1989 Mar 24;56(6):1063-72 [2466576.001]
  • [Cites] Immunol Today. 1989 Dec;10(12):423-8 [2695102.001]
  • [Cites] Cell. 1990 Jun 29;61(7):1303-13 [1694723.001]
  • [Cites] Cell. 1991 Apr 5;65(1):13-24 [1707342.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5292-7 [1717145.001]
  • [Cites] Oncology. 1991;48(5):411-20 [1745490.001]
  • [Cites] Cancer Cells. 1991 Sep;3(9):347-50 [1721518.001]
  • [Cites] Science. 1992 Jul 31;257(5070):682-5 [1496383.001]
  • [Cites] Lancet. 1992 Oct 31;340(8827):1053-8 [1357452.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12160-4 [1465456.001]
  • [Cites] J Cell Biol. 1993 Jan;120(1):227-33 [8416989.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):220-3 [8425758.001]
  • [Cites] Lancet. 1993 Mar 20;341(8847):725-6 [8095628.001]
  • [Cites] Nucleic Acids Res. 1993 Mar 11;21(5):1225-9 [8464707.001]
  • [Cites] J Cell Biol. 1993 Jul;122(2):431-42 [8320265.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4197-203 [7689929.001]
  • [Cites] Lancet. 1993 Oct 23;342(8878):1019-22 [7692200.001]
  • [Cites] N Engl J Med. 1993 Dec 23;329(26):1965 [7504209.001]
  • [Cites] J Cell Biol. 1994 Jan;124(1-2):71-82 [7507492.001]
  • [Cites] BMJ. 1994 Mar 5;308(6929):619-24 [8148709.001]
  • [Cites] Lancet. 1994 Nov 26;344(8935):1470-2 [7526103.001]
  • [Cites] Lancet. 1995 Mar 11;345(8950):615-9 [7534855.001]
  • [Cites] J Pathol. 1995 Sep;177(1):11-20 [7472774.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Jun;122(6):627-32 [8639294.001]
  • [Cites] Virchows Arch. 1996 Nov;429(4-5):191-5 [8972753.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1287-93 [9083148.001]
  • [Cites] Jpn J Cancer Res. 1998 Mar;89(3):283-90 [9600122.001]
  • [Cites] Gastroenterology. 1998 Jun;114(6):1196-205 [9609756.001]
  • [Cites] Jpn J Cancer Res. 1998 Oct;89(10):1033-40 [9849582.001]
  • [Cites] Cell. 1989 Mar 24;56(6):1057-62 [2466575.001]
  • (PMID = 10601048.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Protein Isoforms
  • [Other-IDs] NLM/ PMC1727790
  •  go-up   go-down


3. Makino T, Yamasaki M, Takeno A, Shirakawa M, Miyata H, Takiguchi S, Nakajima K, Fujiwara Y, Nishida T, Matsuura N, Mori M, Doki Y: Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus. Br J Cancer; 2009 Oct 20;101(8):1298-306
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus.
  • However, recent studies indicate their involvement in cancer progression.
  • METHODS: We evaluated CK18 and its filament partner, CK8 expression, by immunohistochemistry in 210 resected specimens from patients with oesophageal squamous cell carcinoma (OSCC).
  • RESULTS: Neither CK18 nor CK8 was expressed in non-cancerous squamous epithelium whereas proper oesophageal glands expressed both CKs.
  • CK18 expression correlated with poorly differentiated tumours, use of neo-adjuvant chemotherapy, and advanced stage.
  • The significant correlation with prognosis and stable expression in biopsy specimen suggest usefulness of CK18 in selection of treatment strategies for OSCC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / chemistry. Esophageal Neoplasms / chemistry. Keratin-18 / analysis. Keratin-8 / analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1086-92 [18309943.001]
  • [Cites] Int J Oncol. 2009 Jan;34(1):107-15 [19082483.001]
  • [Cites] Surgery. 2008 Nov;144(5):793-802 [19081023.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4592-6 [14673047.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2670-4 [15102669.001]
  • [Cites] Hum Pathol. 2004 May;35(5):576-81 [15138932.001]
  • [Cites] Gut. 2004 Jul;53(7):925-30 [15194636.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):662-8 [15252834.001]
  • [Cites] J Mol Biol. 1981 Dec 25;153(4):933-59 [6177862.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] Am J Pathol. 1984 Jan;114(1):121-30 [6197886.001]
  • [Cites] Cancer Res. 1984 Mar;44(3):1153-7 [6198080.001]
  • [Cites] Cancer Res. 1985 Feb;45(2):841-6 [2578311.001]
  • [Cites] Am J Pathol. 1990 Feb;136(2):329-43 [1689541.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Mar;87(6):2319-23 [1690428.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3188-93 [11306507.001]
  • [Cites] J Cell Sci. 2001 Jul;114(Pt 14):2569-75 [11683385.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):6-10 [11796835.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6A):4195-201 [11911318.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] Hum Pathol. 2002 Nov;33(11):1078-85 [12454811.001]
  • [Cites] Surgery. 2003 May;133(5):486-94 [12773976.001]
  • [Cites] Ann Surg Oncol. 2003 Aug;10(7):754-61 [12900366.001]
  • [Cites] Cancer Lett. 2008 Mar 8;261(1):46-54 [18082938.001]
  • [Cites] Gynecol Oncol. 2008 Mar;108(3):598-602 [18191996.001]
  • [Cites] J Pathol. 1991 Jul;164(3):215-24 [1716305.001]
  • [Cites] Am J Pathol. 1992 Mar;140(3):559-68 [1372155.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 1;90(9):4261-5 [7683431.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5311-4 [7515497.001]
  • [Cites] Histopathology. 1995 Jan;26(1):45-50 [7536179.001]
  • [Cites] Histochem J. 1995 Jan;27(1):69-78 [7536188.001]
  • [Cites] Virchows Arch. 1995;426(4):345-9 [7541275.001]
  • [Cites] Anticancer Res. 1995 May-Jun;15(3):1101-5 [7544088.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):63-9 [8546227.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Dec;4(8):871-6 [8634660.001]
  • [Cites] Cancer Metastasis Rev. 1996 Dec;15(4):445-71 [9034603.001]
  • [Cites] Cancer Metastasis Rev. 1996 Dec;15(4):507-25 [9034607.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Sep;17(3):353-60 [9308922.001]
  • [Cites] Clin Cancer Res. 1996 Nov;2(11):1879-85 [9816144.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):48-51 [9892182.001]
  • [Cites] Histol Histopathol. 1999 Apr;14(2):657-64 [10212826.001]
  • [Cites] Mol Cancer Res. 2005 Jul;3(7):365-71 [16046547.001]
  • [Cites] BMC Cancer. 2006;6:10 [16412231.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 28;343(1):252-9 [16540085.001]
  • [Cites] J Surg Oncol. 2006 Apr 1;93(5):401-9 [16550577.001]
  • [Cites] Dis Esophagus. 2006;19(3):158-63 [16722992.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1403-8 [16835344.001]
  • [Cites] Oncol Rep. 2006 Sep;16(3):473-7 [16865245.001]
  • [Cites] Cell Oncol. 2006;28(4):167-75 [16988472.001]
  • [Cites] Gastric Cancer. 2006;9(4):308-14 [17235634.001]
  • [Cites] Surgery. 2007 May;141(5):570-80 [17462456.001]
  • (PMID = 19755983.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-18; 0 / Keratin-8
  • [Other-IDs] NLM/ PMC2768453
  •  go-up   go-down


Advertisement
4. Tanaka N, Kato H, Inose T, Kimura H, Faried A, Sohda M, Nakajima M, Fukai Y, Miyazaki T, Masuda N, Fukuchi M, Kuwano H: Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma. Br J Cancer; 2008 Nov 4;99(9):1468-75
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma.
  • Hypoxic conditions are known to be associated with resistance to chemotherapy and radiotherapy, and with poor cancer prognosis.
  • We examined CA9 expression in surgical specimens from oesophageal squamous cell carcinoma (ESCC) patients (n=127) using immunohistochemistry and real-time RT-PCR.
  • We also examined CA9 expression and cell proliferation in ESCC cell lines (TE-2, TE-8 and TE-15) and an immortalised human oesophageal cell line (CHEK-1) using real-time RT-PCR, Western blotting, ELISA and MTT assay.
  • Immunohistochemistry, high expression of CA9 was found in 63 of the 127 primary tumour specimens and was correlated with poor outcome (P=0.0003) and more aggressive/less favourable clinicopathological parameters (tumour size (P=0.0235), tumour depth (P<0.0001), regional lymph node metastasis (P=0.0031), distant lymph node metastasis (P=0.0077), stage (P<0.0001) and blood vessel invasion (P=0.006)).
  • It is suggested that control of CA9 expression might improve the effectiveness of chemotherapy and radiotherapy in ESCC.
  • [MeSH-major] Antigens, Neoplasm / analysis. Carbonic Anhydrases / analysis. Carcinoma, Squamous Cell / enzymology. Esophageal Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Biomarkers. Cell Hypoxia. Cell Line, Tumor. Cell Proliferation. Female. Humans. Male. Middle Aged. Prognosis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):473-82 [12560438.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):3977-84 [12553021.001]
  • [Cites] Radiother Oncol. 2003 Apr;67(1):35-44 [12758238.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4641-52 [14581333.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4592-6 [14673047.001]
  • [Cites] J Pathol. 2004 May;203(1):551-8 [15095478.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6160-5 [15342400.001]
  • [Cites] J Enzyme Inhib Med Chem. 2004 Jun;19(3):199-229 [15499993.001]
  • [Cites] Physiol Rev. 1967 Oct;47(4):595-781 [4964060.001]
  • [Cites] Bioessays. 1989 Jun;10(6):186-92 [2500929.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;119(8):441-9 [8509434.001]
  • [Cites] Oncogene. 1994 Oct;9(10):2877-88 [8084592.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):941-3 [8640781.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4509-15 [8813149.001]
  • [Cites] Hum Pathol. 1997 Jun;28(6):740-4 [9191010.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7608-13 [9636197.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12596-601 [9770531.001]
  • [Cites] FEBS Lett. 2004 Nov 19;577(3):439-45 [15556624.001]
  • [Cites] Oncology. 2005;69(1):71-80 [16103736.001]
  • [Cites] J Clin Oncol. 2005 Dec 10;23(35):8932-41 [16219933.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):473-7 [16428489.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):334-40 [16495697.001]
  • [Cites] Lung Cancer. 2006 Apr;52(1):59-66 [16513206.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6421-31 [17085655.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):68-75 [17200340.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):329-33 [17233814.001]
  • [Cites] Radiother Oncol. 1999 Nov;53(2):113-7 [10665787.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2220-4 [10688890.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7075-83 [11156414.001]
  • [Cites] Ann Surg. 2001 Jul;234(1):25-32 [11420480.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3660-8 [11504747.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6394-9 [11522632.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7992-8 [11691824.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3399-403 [11705854.001]
  • [Cites] Cancer Lett. 2002 Mar 8;177(1):21-8 [11809527.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):802-11 [12576453.001]
  • (PMID = 18841153.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / RNA, Messenger; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ PMC2579701
  •  go-up   go-down


5. Anderson SE, Minsky BD, Bains M, Hummer A, Kelsen D, Ilson DH: Combined modality chemoradiation in elderly oesophageal cancer patients. Br J Cancer; 2007 Jun 18;96(12):1823-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined modality chemoradiation in elderly oesophageal cancer patients.
  • We present a single institution experience with 5-FU, mitomycin-C based chemoradiation for the primary treatment of elderly patients with oesophageal cancer.
  • Twenty-five patients with a median age of 77 years (range 66-88) with a diagnosis of stage II-III squamous cell or adenocarcinoma of the oesophagus were treated at Memorial Sloan Kettering from 1996 to 2001 with two cycles of concurrent 5-FU, mitomycin-C and 50.4 Gy.
  • Of the 23 patients evaluable for response, 17 patients (68%) had a negative post-treatment endoscopy and CT scan without evidence of progressive disease.
  • Eleven patients (44%) are alive and 10 (40%) remain without evidence of recurrent or progressive oesophageal cancer at a median follow-up of 35 months.
  • There was no significant difference in overall survival between Charlson score </=2 and those with a score >/=2 (P=0.10).
  • Similar survival was observed for patients with adenocarcinoma or squamous carcinoma.
  • Primary chemoradiation with two cycles of 5-FU, mitomycin-C, and 50.4 Gy in elderly patients is an active regimen with moderate toxicity, despite the advanced age and heavy comorbidity burden of this cohort.
  • Patients with local/regional oesophageal cancer with adequate functional status should not be excluded from potentially curative treatment based on age alone.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Mitomycin / administration & dosage. Survival Analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2002 Mar;9(2):210-4 [11888881.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2109-16 [11596027.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2926-32 [12885811.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):45-52 [14701767.001]
  • [Cites] J Chronic Dis. 1987;40(7):705-12 [3110198.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):29-36 [1704362.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):685-8 [2004944.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Dec 1;30(5):1225-32 [7525520.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):333-8 [8625111.001]
  • [Cites] Ann Thorac Surg. 1997 May;63(5):1423-7 [9146337.001]
  • [Cites] J Clin Epidemiol. 1997 Jun;50(6):725-33 [9250271.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1387-92 [9338461.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):357-64 [9527058.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Oct;116(4):545-53 [9766581.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):269-76 [9788404.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):26-31 [9921970.001]
  • [Cites] Ann Thorac Surg. 2005 Feb;79(2):391-7; discussionn 391-7 [15680801.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] World J Gastroenterol. 2006 Feb 28;12(8):1296-9 [16534889.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):455-62 [10653860.001]
  • [Cites] J Am Coll Surg. 2000 May;190(5):562-72; discussion 572-3 [10801023.001]
  • [Cites] Ann Thorac Surg. 2001 Feb;71(2):414-8 [11235680.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 [11390534.001]
  • [Cites] Dis Esophagus. 2003;16(2):90-3 [12823204.001]
  • (PMID = 17533399.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2359964
  •  go-up   go-down


6. Farzad M, De Luca MC, Rubino G, Pirtoli L, Pepi F, Sebaste L, Ponticelli P, Atzeni G, Maranzano E, Silvano G: [Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice]. Radiol Med; 2001 Jul-Aug;102(1-2):72-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice].
  • [Transliterated title] L'intento di cura radicale del carcinoma esofageo al III e IV stadio con radioterapia e chemioterapia concomitanti nella pratica clinica comune.
  • PURPOSE: Chemotherapy and concurrent irradiation, intended to cure, are presently standard treatments for non metastatic, unresectable oesophageal cancer.
  • The results of the combined therapy are superior to those of radiotherapy alone, attaining 25-35% 2-year survival rates.
  • However these results mainly refer to stage I and II tumours as most of the available literature has focussed on these groups.
  • The aim of our report is to present our experience with Stage III and IV patients.
  • MATERIAL AND METHODS: Sixty-four Stage III and IV oesophageal cancer patients were referred to our Departments from January 1, 1990 to December 31, 1996.
  • Diagnosis was obtained through oesophagoscopy and biopsy, stage was assessed by physical examination, chest CT scan, bronchoscopy, barium X-ray examination, upper abdomen ultrasonography and bone nuclide scan.
  • The case features were as follows: histology of squamous cell carcinoma in 32 cases, of adenocarcinoma in 2; tumour in the upper third of the oesophagus in 11 (32.5%), in the middle third in 18 (53%), in the lower third in 5 (14.5%); male/female ratio 29/5, age 48-68 years (mean 56), Karnofsky performance status of 60% or higher.
  • Twenty-one had Stage III (61.75%) and 13 stage IV (38.25%) cancer, with metastasis limited to the supraclavicular or coeliac nodes, which could be included in the radiation volume.
  • In all cases chemotherapy consisted of 5-Fluoruracil (administered in a continuous i.v. infusion, from day 1 to 5, with a 750-1.000 mg/n.sq daily dose) and Cisplatin (75-100 mg/n.sq on the first day, or 20 mg/n.sq for 5 consecutive daily doses, administered by i.v. bolus).
  • Irradiation started with the first cycle of chemotherapy in 5 patients, with the second or third cycle in 29.
  • At least two cycles of chemotherapy were administered during the course of radiation.
  • Radiotherapy was performed with 4 to 18 MeV linear accelerator X-rays, or telecobalt, through opposite anterior and posterior treatment portals or more complex field arrangements.
  • The doses were in the range of 44-66 Gy, with fractionation of 5x180-200 cGy weekly sessions.
  • After treatment, periodic follow-up controls were carried out in all cases.
  • Data on improvement of swallowing were always available, however, and the early therapeutic results were analysed accordingly.
  • Two-year survival after conclusion of the treatment was calculated according to Kaplan and Maier.
  • Survival was analysed (log-rank test) according to stage, Performance Status, oesophagectomy and body weight loss.
  • RESULTS: After treatment, subjective symptomatic relief occurred in 17 of the 22 patients presenting dysphagia (77.5%).
  • Acute toxicity (Grade III or IV WHO) of the treatment accounted for 47% of hematologic adverse effects, 40% of mucositis, 20.5% of vomiting or diarrhoea not responding to drug treatment.
  • Treatment delays of more than one week, due to toxicity, occurred in 23.5%.
  • Overall 2 year survival was 13%, with a median value of 10 months.
  • Survival analysis, according to stage, showed 2 year values of 24% in Stage III and 0% in Stage IV (p=0.09).
  • Six patients showed a remarkable improvement in symptoms and general conditions after treatment, and were restaged with oesophagoscopy, thoracic CT scan and bronchoscopy, which evidenced resectable residual tumors, and they were then operated.
  • DISCUSSION AND CONCLUSIONS: Many Stage III and IV patients, selected for an aggressive chemo-radiation approach on the grounds of satisfactory medical conditions, can obtain relief of dysphagia.
  • Some cases, without extrathoracic spread of the tumor can achieve long term survival (in our experience 24% 2-year survival in Stage III, in our experience which favourably compares with the results obtained by other authors).
  • Whether surgery may improve the therapeutic results of chemo-radiotherapy in patients whose tumour has become resectable, is an issue that cannot be satisfactorily addressed on the basis of our experience, nor are the results from the available literature exhaustive to this regard.
  • [MeSH-major] Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11677442.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Díaz R, Reynes G, Tormo A, de Juan M, Gironés R, Segura A, Aparicio J, Richart P, de la Cueva H, García J: Long-term results of neoadjuvant chemotherapy and combined chemoradiotherapy before surgery in the management of locally advanced oesophageal cancer: a single-centre experience. Clin Transl Oncol; 2009 Dec;11(12):835-41
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of neoadjuvant chemotherapy and combined chemoradiotherapy before surgery in the management of locally advanced oesophageal cancer: a single-centre experience.
  • INTRODUCTION: Neoadjuvant chemoradiotherapy before surgery is an option in the treatment of locally advanced resectable oesophageal cancer (EC).
  • METHODS: This was a prospective, single-centre study of neoadjuvant chemotherapy and concomitant chemoradiotherapy with CDDP and 5-FU and 50.4 Gy of external radiotherapy before possible radical surgery in patients with locally advanced resectable EC.
  • If surgery was not possible, a second-phase radiotherapy boost of 10 Gy and one cycle of modified dose chemotherapy were used.
  • RESULTS: Seventy-three patients included between 1998 and 2007: 96% males, median age 61, 83% squamous cell carcinomas, 23% lower third tumours, 36% stage II and 54% stage III and 47% local lymph node involvement.
  • The achievement of a complete response is a powerful prognostic factor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Esophageal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Algorithms. Combined Modality Therapy. Disease Progression. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoadjuvant Therapy. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] Radiology. 2005 Sep;236(3):841-51 [16118165.001]
  • [Cites] Ann Thorac Surg. 1999 Dec;68(6):2059-64 [10616977.001]
  • [Cites] Dis Esophagus. 2000;13(4):293-300 [11284977.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):161-7 [9219702.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):906-12 [10201455.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2310-7 [15800321.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jul;17(1):49-54 [2745207.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):659-68 [16129366.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):226-34 [17329193.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1160-8 [17401004.001]
  • [Cites] Gut. 2001 Oct;49(4):534-9 [11559651.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Jul;112(1):130-6 [8691857.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Br J Surg. 1998 Jul;85(7):999-1001 [9692583.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1167-74 [11870157.001]
  • [Cites] Radiology. 1991 Nov;181(2):419-25 [1924783.001]
  • [Cites] Ann Thorac Surg. 1987 Aug;44(2):119-22 [3619535.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 20045790.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


8. Morgan MA, Lewis WG, Casbard A, Roberts SA, Adams R, Clark GW, Havard TJ, Crosby TD: Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma. Br J Surg; 2009 Nov;96(11):1300-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma.
  • BACKGROUND: Definitive chemoradiotherapy (dCRT) has been proposed as an alternative therapy for selected patients with oesophageal cancer.
  • The aim of this study was to determine the outcomes of dCRT, surgery alone, and neoadjuvant chemotherapy followed by surgery (CS) in patients with oesophageal cancer.
  • METHODS: Consecutive patients diagnosed with oesophageal cancer and managed by a multidisciplinary team were staged by computed tomography and endoluminal ultrasonography.
  • The primary outcome measure was overall survival measured from date of diagnosis.
  • CONCLUSION: These findings support the need for a randomized trial of dCRT versus CS for resectable oesophageal cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant / mortality. Esophagectomy / mortality. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant / mortality. Survival Analysis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Surg. 2010 May;97(5):792-3; author reply 793 [20393986.001]
  • (PMID = 19847875.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Tougeron D, Di Fiore F, Hamidou H, Rigal O, Paillot B, Michel P: Response to definitive chemoradiotherapy and survival in patients with an oesophageal adenocarcinoma versus squamous cell carcinoma: a matched-pair analysis. Oncology; 2007;73(5-6):328-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to definitive chemoradiotherapy and survival in patients with an oesophageal adenocarcinoma versus squamous cell carcinoma: a matched-pair analysis.
  • OBJECTIVES: The impact of the histological tumour type in patients treated with definitive chemoradiotherapy (CRT) for an oesophageal cancer is not well established.
  • The aim of this retrospective matched-pair analysis was to evaluate the clinical complete response (CCR) to definitive CRT and the outcome between 2 groups of patients.
  • METHODS: Fifty-seven patients with an oesophageal adenocarcinoma (ADC) were matched according to the tumour stage and the WHO performance as well as the CRT regimen status including 57 patients with an oesophageal squamous cell carcinoma (SCC).
  • CRT was based on radiotherapy combined with a cisplatin-based chemotherapy.
  • CONCLUSION: Our study showed that treatment completion and CCR to definitive CRT were more frequent in SCC with, however, more local recurrences in these patients.
  • Further studies are required to confirm this difference in response rate to definitive CRT according to histological type of the tumour in oesophageal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Deglutition Disorders / epidemiology. Female. France / epidemiology. Humans. Incidence. Male. Middle Aged. Prognosis. Retrospective Studies. Smoking / adverse effects. Smoking / epidemiology. Survival Analysis. Treatment Outcome


10. Mariette C, Piessen G, Lamblin A, Mirabel X, Adenis A, Triboulet JP: Impact of preoperative radiochemotherapy on postoperative course and survival in patients with locally advanced squamous cell oesophageal carcinoma. Br J Surg; 2006 Sep;93(9):1077-83
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of preoperative radiochemotherapy on postoperative course and survival in patients with locally advanced squamous cell oesophageal carcinoma.
  • BACKGROUND: The aim of this study was to determine the effect of neoadjuvant radiochemotherapy (RCT) on postoperative complications and survival after surgery for locally advanced oesophageal squamous cell carcinoma.
  • METHODS: Postoperative course and survival were compared in 144 patients who had neoadjuvant RCT and 80 control patients who had surgery alone for locally advanced oesophageal squamous cell carcinoma (radiological stage T3, N0 or N1, M0).
  • CONCLUSION: Neoadjuvant RCT significantly enhanced R0 resection and survival rates in patients with stage T3 oesophageal squamous cell carcinoma, with no increase in postoperative mortality and morbidity rates.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Complications / prevention & control. Preoperative Care / methods. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 British Journal of Surgery Society Ltd.
  • (PMID = 16779882.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Bitzer M, Stahl M, Arjumand J, Rees M, Klump B, Heep H, Gabbert HE, Sarbia M: C-myc gene amplification in different stages of oesophageal squamous cell carcinoma: prognostic value in relation to treatment modality. Anticancer Res; 2003 Mar-Apr;23(2B):1489-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-myc gene amplification in different stages of oesophageal squamous cell carcinoma: prognostic value in relation to treatment modality.
  • BACKGROUND: The proto-oncogene c-myc is known to be involved in the regulation of proliferation, apoptosis and cell differentiation.
  • MATERIALS AND METHODS: Amplification of c-myc was determined by means of differential PCR in 77 surgically treated stage I or II oesophageal squamous cell carcinomas (SCC) as well as in 43 locally advanced SCC (cT3-4 cN0-1 cM0) treated by radiochemotherapy and facultatively by surgery.
  • Among the surgically treated tumours, the presence of c-myc amplification was correlated with high proliferative activity (p = 0.0399) but not with overall survival.
  • Among the multimodally treated SCC, c-myc amplification tended to be correlated with response to chemotherapy and response to radiochemotherapy (not significant) whereas no impact on overall survival was found.
  • CONCLUSION: Amplification of c-myc is found more frequently in advanced stages of oesophageal SCC than in early stages.
  • C-myc amplification, however, does not influence the overall survival of oesophageal SCC patients treated either by surgery alone or by multimodal therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Esophageal Neoplasms / genetics. Gene Amplification. Genes, myc
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Division. Cisplatin / administration & dosage. Clinical Trials as Topic. Combined Modality Therapy. Disease Progression. Esophagectomy. Etoposide / administration & dosage. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Multicenter Studies as Topic. Polymerase Chain Reaction. Prognosis. Prospective Studies. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12820414.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; FLEP regimen
  •  go-up   go-down


12. Servagi-Vernat S, Bosset M, Crehange G, Buffet-Miny J, Puyraveau M, Maingon P, Mercier M, Bosset JF: Feasibility of chemoradiotherapy for oesophageal cancer in elderly patients aged &gt;or=75 years: a prospective, single-arm phase II study. Drugs Aging; 2009;26(3):255-62
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of chemoradiotherapy for oesophageal cancer in elderly patients aged >or=75 years: a prospective, single-arm phase II study.
  • BACKGROUND: The number of elderly patients with oesophageal cancer is expected to increase with the aging of the population and the rapidly increasing incidence of adenocarcinoma.
  • Surgical resection is standard treatment for patients with localized disease considered fit for operation.
  • However, elderly patients with oesophageal cancer are rarely referred for surgery.
  • The aim of this prospective, single-arm, phase II study was to evaluate the feasibility and efficacy (tumour response) of chemoradiotherapy in the treatment of elderly patients with localized oesophageal cancer.
  • METHODS: The main study inclusion criteria were: patients aged >or=75 years; oesophageal cancer disease stage II-III; Charlson co-morbidity index score <or=4; Eastern Cooperative Oncology Group (ECOG) performance status 0-2; and weight loss <15%.
  • The radiotherapy regimen consisted of 50 Gy over 5 weeks.
  • The mean age of the patients was 79.4 years (range 75-89 years), 18 were male (81.8%), 15 had squamous cell carcinoma (68%) and 11 had stage IIA disease (50%).
  • All patients were compliant with the planned treatment, including doses and timing.
  • During treatment, ECOG performance status remained stable during the first 3 weeks and worsened slightly over the last 2 weeks.
  • Six weeks after treatment, 14 patients were in complete response (63.6%) and 8 patients (36.4%) had no treatment effect.
  • Four patients (18.2%) were alive without disease from 2.6 to 5.5 years after treatment.
  • In 14 evaluable patients, QOL 6 weeks after treatment was slightly altered by treatment.
  • CONCLUSIONS: The results of this prospective phase II study support the feasibility of chemoradiotherapy for oesophageal cancer in carefully selected elderly patients, with the potential for a curative effect.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Prospective Studies. Quality of Life. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 1998 Oct;116(4):545-53 [9766581.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2347-54 [15160337.001]
  • [Cites] Gut. 1982 Dec;23(12):1060-7 [6184269.001]
  • [Cites] Ann R Coll Surg Engl. 1988 Jan;70(1):34-7 [3408136.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):161-7 [9219702.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):988-95 [10699886.001]
  • [Cites] Eur J Cancer. 1996 Oct;32A(11):1912-7 [8943674.001]
  • [Cites] Dis Esophagus. 2003;16(2):90-3 [12823204.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6461-8 [14695149.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):357-64 [9527058.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 Sep;32(3):445-8 [17643999.001]
  • [Cites] Br J Cancer. 2007 Jun 18;96(12):1823-7 [17533399.001]
  • [Cites] Radiother Oncol. 1999 May;51(2):133-9 [10435804.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):769-75 [9240645.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] N Engl J Med. 2001 Dec 27;345(26):1890-900 [11756581.001]
  • [Cites] J Gastrointest Surg. 2004 May-Jun;8(4):448-53 [15120370.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1167-74 [11870157.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):92-8 [12506176.001]
  • [Cites] Semin Radiat Oncol. 2007 Jan;17(1):2-9 [17185192.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Ann Thorac Surg. 2006 Dec;82(6):2031-6; discussion 2036 [17126106.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v61-118 [14684501.001]
  • (PMID = 19358620.001).
  • [ISSN] 1170-229X
  • [Journal-full-title] Drugs & aging
  • [ISO-abbreviation] Drugs Aging
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Font A, Arellano A, Fernández-Llamazares J, Casas D, Boix J, Cardenal J, Margelí M, Manzano JL, Abad A, Rosell R: Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer. Clin Transl Oncol; 2007 Mar;9(3):177-82
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer.
  • INTRODUCTION: To evaluate the efficacy and tolerability of weekly docetaxel concurrent with radiotherapy in inoperable oesophageal cancer patients.
  • MATERIAL AND METHODS: Thirty-four oesophageal cancer patients with co-morbid medical conditions, locally advanced tumours (T4) or advanced age (older than 75 years) received docetaxel (20 mg/m2 weekly) plus concurrent radiotherapy (2 Gy daily, to a total dose of 66 Gy).
  • Twenty-two patients (64%) were stage III, 19 of whom had T4 tumours.
  • RESULTS: Twenty-seven patients (79%) completed the planned chemoradiotherapy treatment.
  • There were two treatment-related deaths due to radiation pneumonitis.
  • CONCLUSIONS: Docetaxel plus concurrent radiotherapy is active in poor-prognosis oesophageal cancer patients, with a lower incidence of severe oesophagitis than with cisplatin-based chemoradiotherapy regimens.
  • This schedule can be considered, especially in patients with non-T4 tumours who are not candidates for oesophageal resection.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy. Radiotherapy, High-Energy. Taxoids / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Comorbidity. Drug Administration Schedule. Esophagitis / etiology. Female. Hematologic Diseases / etiology. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Radiation Pneumonitis / etiology. Remission Induction. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403629.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


15. van Vliet EP, Eijkemans MJ, Steyerberg EW, Kuipers EJ, Tilanus HW, van der Gaast A, Siersema PD: The role of socio-economic status in the decision making on diagnosis and treatment of oesophageal cancer in The Netherlands. Br J Cancer; 2006 Nov 6;95(9):1180-5
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of socio-economic status in the decision making on diagnosis and treatment of oesophageal cancer in The Netherlands.
  • In the United States (USA), a correlation has been demonstrated between socio-economic status (SES) of patients on the one hand, and tumour histology, stage of the disease and treatment modality of various cancer types on the other hand.
  • It is unknown whether such correlations are also involved in patients with oesophageal cancer in The Netherlands.
  • Between 1994 and 2003, 888 oesophageal cancer patients were included in a prospective database with findings on the diagnostic work-up and treatment of oesophageal cancer.
  • Linear-by-linear association testing revealed that oesophageal adenocarcinoma was more frequently observed in patients with higher SES and squamous cell carcinoma in patients with lower SES (P=0.02).
  • Multivariable logistic regression analysis showed no correlation between SES and staging procedures and preoperative TNM stage.
  • Patients with a higher SES more frequently underwent resection or were treated with chemotherapy (OR: 1.15; 95% CI 1.01-1.32 and OR: 1.16; 95% CI 1.02-1.32, respectively).
  • Socio-economic factors are involved in oesophageal cancer in The Netherlands, as patients with a higher SES are more likely to have an adenocarcinoma and patients with a lower SES a squamous cell carcinoma.
  • Moreover, the correlations between SES and different treatment modalities suggest that both patient and doctor determinants contribute to the decision on the most optimal treatment modality in patients with oesophageal cancer.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / therapy. Social Class
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Databases as Topic / statistics & numerical data. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Netherlands. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Care. 2002 Jan;40(1 Suppl):I14-26 [11789626.001]
  • [Cites] Surg Oncol. 2001 Nov;10(3):103-11 [11750229.001]
  • [Cites] South Med J. 2002 Aug;95(8):900-8 [12190229.001]
  • [Cites] Arch Intern Med. 2003 Jan 13;163(1):49-56 [12523916.001]
  • [Cites] Med Care. 2003 Jul;41(7):842-52 [12835608.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2):235-43 [14762861.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):78-93 [15061598.001]
  • [Cites] Cancer Causes Control. 2004 Aug;15(6):601-9 [15280639.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):450-64 [15297938.001]
  • [Cites] Scand J Public Health. 2004;32(4):250-6 [15370764.001]
  • [Cites] N Engl J Med. 1988 Mar 10;318(10):612-7 [2830514.001]
  • [Cites] Gastrointest Radiol. 1992 Fall;17(4):305-10 [1426845.001]
  • [Cites] Am J Surg. 1993 May;165(5):558-60 [8488936.001]
  • [Cites] Chest. 1998 Mar;113(3):687-95 [9515844.001]
  • [Cites] Br J Surg. 1998 Jul;85(7):994-8 [9692582.001]
  • [Cites] Med Care. 1998 Sep;36(9):1337-48 [9749657.001]
  • [Cites] Health Policy. 1998 Sep;45(3):221-38 [10338953.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):20-9 [9934727.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1198-205 [10519898.001]
  • [Cites] Laryngoscope. 2005 Jan;115(1):125-31 [15630380.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):510-7 [15659496.001]
  • [Cites] Health Econ. 2005 Jun;14(6):595-608 [15497191.001]
  • [Cites] Soc Sci Med. 2006 Jan;62(2):317-28 [16039765.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):234-42 [16454824.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2378-90 [10590381.001]
  • [Cites] Ethn Dis. 2000 Spring-Summer;10(2):248-56 [10892832.001]
  • [Cites] Clin Radiol. 2000 Sep;55(9):696-701 [10988048.001]
  • [Cites] Am J Epidemiol. 2001 Jan 15;153(2):114-22 [11159155.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Med Care. 2002 Aug;40(8):717-24 [12187185.001]
  • (PMID = 17031405.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2360583
  •  go-up   go-down


16. Lyratzopoulos G, Barbiere JM, Gajperia C, Rhodes M, Greenberg DC, Wright KA: Trends and variation in the management of oesophagogastric cancer patients: a population-based survey. BMC Health Serv Res; 2009 Dec 15;9:231
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends and variation in the management of oesophagogastric cancer patients: a population-based survey.
  • BACKGROUND: Previous evidence indicates potential variation in the quality of care of cancer patients.
  • We aimed to examine whether recent changes in the treatment of oesophagogastric cancers have been distributed equally among different patient subgroups.
  • METHODS: We analysed population-based cancer registry data about the treatment patterning of oesophagogastric cancer (other than oesophageal squamous cell carcinoma) during 1995-2006.
  • There was only limited information on stage, and no information on co-morbidity status.
  • During successive triennia, curative surgery use decreased from 28% to 20% (p < 0.001) whilst chemotherapy use increased from 9% to 30% (p < 0.001).
  • In multivariable logistic regression adjusting for age group, gender, diagnosis period and tumour type, curative surgery and chemotherapy were used less frequently in more deprived patients [per increasing deprivation group Odds Ratio (OR) = 0.96, 95% Confidence Interval (CI) 0.93-0.99, and OR = 0.90, 95%CI 0.87-0.93, respectively, p < 0.001 for both)].
  • Chemotherapy was also used less frequently in women (OR = 0.76, p < 0.001).
  • CONCLUSIONS: During the study period, curative surgery decreased by a third and chemotherapy use increased by more than three-fold, reflecting improvements in the appropriateness and quality of management, but chemotherapy use, in particular, was unequal, both by socioeconomic status and gender.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Gastroenterol Hepatol. 2005 Mar;3(3):225-30 [15765441.001]
  • [Cites] Colorectal Dis. 2004 Nov;6(6):512-7 [15521945.001]
  • [Cites] Scand J Gastroenterol. 2005 Nov;40(11):1351-7 [16334445.001]
  • [Cites] Ann Oncol. 2006 Jan;17(1):5-19 [16143594.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1180-5 [17031405.001]
  • [Cites] Eur J Cancer. 2007 Feb;43(3):565-75 [17140789.001]
  • [Cites] Scand J Gastroenterol. 2007 Oct;42(10):1230-7 [17852847.001]
  • [Cites] J Clin Epidemiol. 2008 Mar;61(3):261-267 [18226749.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):222-31 [18282806.001]
  • [Cites] Br J Cancer. 2008 Sep 23;99 Suppl 1:S11-3 [18813240.001]
  • [Cites] Br J Cancer. 2008 Sep 23;99 Suppl 1:S16-8 [18813246.001]
  • [Cites] Br J Cancer. 2008 Dec 2;99(11):1923-8 [19034284.001]
  • [Cites] Health Stat Q. 2008 Winter;(40):91-7 [19093643.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):915-21 [19223561.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):351-69 [19303813.001]
  • [Cites] Cancer Causes Control. 2009 May;20(4):417-35 [19002764.001]
  • [Cites] Aliment Pharmacol Ther. 2009 Oct 15;30(8):873-80 [19624549.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] BMJ. 2001 Apr 7;322(7290):830-1 [11290637.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Mar 1;17(5):655-64 [12641514.001]
  • [Cites] Br J Cancer. 2003 Sep 1;89(5):828-30 [12942112.001]
  • [Cites] J Epidemiol Community Health. 2004 Jul;58(7):623-5 [15194729.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Jul;16(7):681-8 [15201582.001]
  • [Cites] Br J Cancer. 2005 Apr 11;92(7):1279-82 [15798765.001]
  • (PMID = 20003488.001).
  • [ISSN] 1472-6963
  • [Journal-full-title] BMC health services research
  • [ISO-abbreviation] BMC Health Serv Res
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2813235
  •  go-up   go-down


17. Zhao KL, Liu G, Jiang GL, Wang Y, Zhong LJ, Wang Y, Yao WQ, Guo XM, Wu GD, Zhu LX, Shi XH: Association of haemoglobin level with morbidity and mortality of patients with locally advanced oesophageal carcinoma undergoing radiotherapy--a secondary analysis of three consecutive clinical phase III trials. Clin Oncol (R Coll Radiol); 2006 Oct;18(8):621-7
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of haemoglobin level with morbidity and mortality of patients with locally advanced oesophageal carcinoma undergoing radiotherapy--a secondary analysis of three consecutive clinical phase III trials.
  • AIMS: To investigate the strength of association between anaemia and overall survival, locoregional control, and late radiation complications in patients with locally advanced oesophageal carcinoma undergoing radiotherapy with or without chemotherapy and hyperthermia.
  • MATERIALS AND METHODS: Between March 1996 and December 2002, 303 patients with locally advanced squamous cell carcinoma of oesophagus enrolled in three consecutive prospective phase III trials conducted in our department were included in this study.
  • These patients received one of the following four irradiation schedules: late course accelerated hyperfractionated (LCAF) radiotherapy alone, LCAF combined with concurrent chemotherapy, LCAF combined with hyperthermia, and continuous accelerated hyperfractionated (CAHF) radiotherapy according to each protocol.
  • From multivariate analyses, T stage, location of tumour and haemoglobin level were found to be independent predictors for survival.
  • T stage, gender and haemoglobin level were independent predictors for locoregional control.
  • CONCLUSIONS: For patients with locally advanced oesophageal carcinoma undergone irradiation, anaemia associated a statistically significant reduction in survival and locoregional control rates, but also decreased radiation toxicity rates.
  • [MeSH-major] Anemia / etiology. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / radiotherapy. Hemoglobins / analysis. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17051953.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hemoglobins
  •  go-up   go-down


18. Denham JW, Steigler A, Kilmurray J, Wratten C, Burmeister B, Lamb DS, Joseph D, Delaney G, Christie D, Jamieson G, Smithers BM, Ackland S, Walpole E: Relapse patterns after chemo-radiation for carcinoma of the oesophagus. Clin Oncol (R Coll Radiol); 2003 May;15(3):98-108
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse patterns after chemo-radiation for carcinoma of the oesophagus.
  • AIM: The detailed review of patterns of failure in this report was undertaken to identify the continuing obstacles to the successful management of oesophageal cancer, and to establish whether there is a case to compare definitive chemo-radiation (Def-CR) and surgery for patients with squamous cancer in a randomized controlled trial.
  • MATERIALS AND METHODS: First and subsequent sites of failure were reviewed in 274 patients treated with Def-CR using two cycles of cisplatin, infusional fluorouracil and 60 Gy; and 92 patients with limited chemo-radiation (CR), using one cycle and 35 Gy, followed by surgery (CR-Surg).
  • Failure patterns were analysed using competing risks methodology, and pre-treatment variables predicting survival were identified by proportional hazards modelling.
  • RESULTS: Site, stage, performance status and gender were independently predictive of survival following Def-CR.
  • Lowest rates of local and distant failure at 5 years (29.9% and 26%) occurred in patients with squamous cancer (SCC) located in the upper-third, whose 5-year survival was also the most favourable (49.2%).
  • Local failure occurred in 31.5% of patients undergoing CR-Surg but distant failure in isolation was observed in a further 34.7%.
  • Patients with no residual cancer in the resection specimen had the lowest rates of local (0%) and distant (16.7%) failure and the best survival (64.9%).
  • Survival in patients with residual cancer in nodes, however, was extremely poor (3.5%) with distant failure occurring in 66.7%.
  • CONCLUSION: The concurrent administration of chemotherapy with radiotherapy seems to have improved loco-regional control and has exposed distant failure as an obstacle to further improvements in outcome.
  • Site, histological subtype, gender and response to chemo-radiation may predict biological differences in oesophageal cancer (OC) that influence outcome.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Male. Middle Aged. Prognosis. Randomized Controlled Trials as Topic. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12801045.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Kolh P, Honore P, Degauque C, Gielen J, Gerard P, Jacquet N: Early stage results after oesophageal resection for malignancy - colon interposition vs. gastric pull-up. Eur J Cardiothorac Surg; 2000 Sep;18(3):293-300
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early stage results after oesophageal resection for malignancy - colon interposition vs. gastric pull-up.
  • OBJECTIVE: The aims of our study were to determine if using the colon as a digestive transplant after oesophagectomy for cancer was associated with increased postoperative complications, and to assess the impact of preoperative radiochemotherapy on postoperative hospital outcome.
  • METHODS: From January 1990 to December 1998, 130 patients underwent oesophageal resection for malignancy.
  • Indications were squamous cell carcinoma in 69 patients and adenocarcinoma in 61.
  • Preoperatively 30 patients (eight in stage IIB, 18 in stage III, and four in stage IV) received radiochemotherapy.
  • There were 84 subtotal oesophagectomies, with anastomosis in the neck in 44 patients and at the thoracic inlet in 40, and 46 distal oesophageal resections.
  • The incidence of postoperative pulmonary complications was 70% (21/30 patients) in the subgroup who received preoperative radiochemotherapy, as compared to 11% (5/44 patients) in the subgroup of comparable staging, but without preoperative treatment (P<0.001).
  • Our results suggest that preoperative neoadjuvant treatment significantly increases postoperative pulmonary complications.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Colon / transplantation. Esophageal Neoplasms / surgery. Esophagus / surgery. Stomach / surgery
  • [MeSH-minor] Anastomosis, Surgical / methods. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagectomy. Female. Hospital Mortality. Humans. Male. Middle Aged. Palliative Care. Reoperation. Retrospective Studies. Stomach Neoplasms / drug therapy. Stomach Neoplasms / mortality. Stomach Neoplasms / radiotherapy. Stomach Neoplasms / surgery. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10973538.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


20. Davies L, Lewis WG, Arnold DT, Escofet X, Blackshaw G, Gwynne S, Evans M, Roberts SA, Appadurai I, Crosby TD: Prognostic significance of age in the radical treatment of oesophageal cancer with surgery or chemoradiotherapy: a prospective observational cohort study. Clin Oncol (R Coll Radiol); 2010 Sep;22(7):578-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of age in the radical treatment of oesophageal cancer with surgery or chemoradiotherapy: a prospective observational cohort study.
  • AIMS: To compare the outcomes of stage-directed surgical therapy and chemoradiotherapy (CRT) for oesophageal cancer and to determine if a significant age-treatment interaction exists to guide therapy.
  • MATERIALS AND METHODS: Five hundred and eight consecutive patients with oesophageal cancer suitable for radical treatment based on radiological stage and performance status were studied (275 surgery; 93 surgery alone, 131 neoadjuvant chemotherapy, 51 neoadjuvant CRT and 233 definitive CRT).
  • Multivariate analysis including only surgical patients in the model revealed three factors to be independently and significantly associated with survival; endoscopic ultrasound (EUS) T stage (P=0.033), EUS lymph node metastasis count (>or=2 versus 0: hazard ratio 1.67, 95% confidence interval 1.06-2.92, P=0.026), and age>or=70 years (hazard ratio 1.51, 95% confidence interval 1.05-2.16, P=0.025).
  • CONCLUSION: Overall survival for patients treated with surgery was strongly age dependent around the age of 70 years, and patients>or=70 years with oesophageal cancer should be aware that outcomes after CRT are similar to those after surgery.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy. Esophagectomy. Radiotherapy Dosage
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cisplatin / administration & dosage. Cohort Studies. Combined Modality Therapy. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Prospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20591633.001).
  • [ISSN] 1433-2981
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Dabrowski A, Filip A, Zgodziński W, Dabrowska M, Polańska D, Wójcik M, Zinkiewicz K, Wallner G: Assessment of prognostic significance of cytoplasmic survivin expression in advanced oesophageal cancer. Folia Histochem Cytobiol; 2004;42(3):169-72
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of prognostic significance of cytoplasmic survivin expression in advanced oesophageal cancer.
  • Expression of survivin was found in colorectal cancer, neuroblastoma, bladder cancer, non-small cell lung cancer, and breast cancer.
  • There is some recent data indicating the correlation of poor prognosis and worse response to chemotherapy in patients with oesophageal squamous cell carcinoma (OSCC) expressing survivin.
  • The aim of the present study was to assess survivin expression in cancerous tissue of patients with advanced OSCC and to test the potential correlation between survivin expression and clinicopathological data.
  • Forty two patients (mean age 58.36+/-8.97 yrs), who were oesophagectomised due to squamous cell carcinoma of the thoracic oesophagus between 1998 and 2000, were retrospectively analysed.
  • No statistically significant correlation between survivin expression in the tumour and patients' gender, TNM stage, or vascular involvement was noted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15493578.001).
  • [ISSN] 0239-8508
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


22. Black E, Niamat J, Boddu S, Martin-Ucar A, Duffy JP, Morgan WE, Beggs FD: Unplanned splenectomy during oesophagectomy does not affect survival. Eur J Cardiothorac Surg; 2006 Feb;29(2):244-7
Hazardous Substances Data Bank. PENICILLIN V .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study is to identify the factors associated with a likelihood of inadvertent splenectomy and its influence on early and long-term outcome in patients having oesophagectomy for oesophageal carcinoma.
  • Neoadjuvant chemotherapy was administered to a minority of patients; none subsequently had splenectomy.
  • There were significant differences between types of operation (Ivor-Lewis 18 (9.0%), left thoracolaparotomy 14 (9.9%) and left thoracophrenotomy 15 (3.9%), p=0.01).
  • Splenectomy was more common with advanced N stage disease (OR=0.44 [0.20-0.95]; p=0.04).
  • Type of operation and advanced N stage are important risks for splenectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy. Splenectomy
  • [MeSH-minor] Aged. Female. Hospital Mortality. Humans. Length of Stay. Male. Middle Aged. Neoplasm Staging. Penicillin V / therapeutic use. Penicillins / therapeutic use. Proportional Hazards Models. Prospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. PENICILLIN VK .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16388954.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Penicillins; Z61I075U2W / Penicillin V
  •  go-up   go-down






Advertisement